Alternative solution for menstrual cycle normalization in polycystic ovary syndrome

DOI

https://dx.doi.org/10.18565/aig.2022.6.122-128

Khadzhieva N.Kh.
RZhD-Meditsina Central Clinical Hospital, Moscow, Russia

Objective: To study the effectiveness of using a vitamin-mineral complex (VMC) based on myoinositol (MI) and D-chiroinositol (DCI) in a ratio of 5:1 to normalize the rhythm of menstruation and to restore ovulation.
Materials and methods: Examinations were made in 268 women aged 18 to 39 years (mean age 25.1 (5.3) years) with anovulatory polycystic ovary syndrome (PCOS) phenotypes and a normal body mass index. Phenotype A was detected in 126/268 (47%) women, phenotype B was found in 94/268 (35%), and phenotype D was identified in 48/268 (18%). All the patients included in the study were recommended a VMC based on MI and DCI in a ratio of 5:1 as one sachet taken twice a day for 3 months.
Results: At 3 months after initiation of non-hormonal correction of the menstrual cycle, the restored menstruation rhythm was recorded in 174/268 (64.9%) patients within 24–38 days with a variability of no more than 7 days. Restoration of ovulation was observed in a significant proportion (146/268 (54.5%)) of patients (95% CI [43.4%; 65.7%]) who had taken for three months a VMC based on MI/DCI in a ratio of 5:1, manganese and folic acid (Dikirogen). At the same time, spontaneous ovulation was recorded in 67 (25%) and 100 (37.3%) patients after one and two months, respectively.
The side and undesirable effects, such as nausea and diarrheas, were noted in 1 (0.37%) and 2 (0.74%) patients, respectively.
Conclusion: The use of the VMC based on MI/DCI in a ratio of 5:1 contributed to the normalization of the rhythm of menstruation and to the restoration of ovulation in most women with PCOS who well tolerated the complex.

myoinositol

D-chiroinositol

PCOS

anovulation

oligomenorrhea

amenorrhea

menstrual irregularity

Dikirogen

Full text (in Russian)

Министерство здравоохранения РФ. Клинические рекомендации «Синдром поликистозных яичников». 2021. [Ministry of Health of the Russian Federation. Clinical guidelines “Polycystic ovary syndrome”. 2021. (in Russian)].
Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L. et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018; 110(3): 364-79. https://dx.doi.org/10.1016/j.fertnstert.2018.05.004.
American College of Obstetricians and Gynecologists’ Committee. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet. Gynecol. 2018; 131(6): e157-e171. https://dx.doi.org/10.1097/AOG.0000000000002656. Erratum in: ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome: Correction. Obstet. Gynecol. 2020; 136(3): 638. https://dx.doi.org/10.1097/AOG.0000000000004069.
Chen Y., Fang S.Y. Potential genetic polymorphisms predicting polycystic ovary syndrome. Endocr. Connect. 2018; 7(5): R187-95. https://dx.doi.org/10.1530/EC-18-0121.
Papadakis G., Kandaraki E.A., Garidou A., Koutsaki M., Papalou O., Diamanti-Kandarakis E. et al. Tailoring treatment for PCOS phenotypes. Expert Rev. Endocrinol. Metab. 2021; 16(1): 9-18. https://dx.doi.org/10.1080/17446651.2021.1865152.
Bevilacqua A., Bizzarri M. Inositols in insulin signaling and glucose metabolism. Int. J. Endocrinol. 2018; 25: 1968450. https://dx.doi.org/10.1155/2018/1968450.
Ijuin T., Takenawa T. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP). J. Biol. Chem. 2012; 287(10): 6991-9. https://dx.doi.org/10.1074/jbc.M111.335539.
Kim J.N., Han S.N., Kim H.K. Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells. Nutr. Res. 2014; 34(8): 723-31. https://dx.doi.org/10.1016/j.nutres.2014.07.015.
Пустотина О.А. Применение инозитолов при синдроме поликистозных яичников. Эффективная фармакотерапия. 2020; 16(28): 24-34. [Pustotina O.A. Use of inositols in polycystic ovary syndrome. Effective pharmacotherapy. 2020; 16(28): 24-34.)]. https://dx.doi.org/10.33978/2307-3586-2020-16-28-24-34.
Пустотина О.А., Дикке Г.Б., Остроменский В.В. Роль инозитола в репродукции человека. Акушерство и гинекология. 2022; 2: 111-8. [Pustotina O.A., Dikke G.B., Ostromensky V.V. The role of inositol in human reproduction. Obstetrics and Gynecology. 2022; 2: 111-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.2.111-118.
Громова О.А., Торшин И.Ю., Уварова Е.В., Тапильская Н.Г., Калачева А.Г. Систематический анализ биологических ролей и фармакологических свойств D-хироинозитола. Гинекология. 2020; 22(3): 21-8. [Gromova O.A., Torshin I.Yu., Uvarova E.V., Tapilskaya N.I., Kalacheva A.G. Systematic analysis of the biological oles and pharmacological properties of D-chiro-inositol. Gynecology. 2020; 22(3): 21-8. (in Russian)]. https://dx.doi.org/10.26442/20795696.2020.3.200210.
Gambioli R., Montanino O.M., Nordio M., Chiefari A., Puliani G., Unfer V. New insights into the activities of D-Chiro-Inositol: A narrative review. Biomedicines. 2021; 9(10): 1378. https://dx.doi.org/10.3390/biomedicines9101378.
Gaspers L.D., Pierobon N., Thomas A.P. Intercellular calcium waves integrate hormonal control of glucose output in the intact liver. J. Physiol. 2019; 597(11): 2867-85. https://dx.doi.org/10.1113/JP277650.
Di Segni C., Silvestrini A., Fato R., Bergamini C., Guidi F., Raimondo S. et al. Plasmatic and intracellular markers of oxidative stress in normal weight and obese patients with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes. 2017; 125(8): 506-13. https://dx.doi.org/10.1055/s-0043-111241.
Даренская М.А., Колесников С.И., Гребенкина Л.А., Данусевич И.Н., Лазарева Л.М., Наделяева Я.Г., Даржаев З.Ю., Никитина О.А., Базарова Т.А., Колесникова Л.И. Анализ про- и антиоксидантной активности крови у женщин с различными фенотипами синдрома поликистозных яичников и бесплодием. Акушерство и гинекология. 2017; 8: 86-91. [Darenskaya M.A., Kolesnikov S.I., Grebenkina L.A., Danusevich I.N., Lazareva L.M., Nadelyaeva Ya.G. et al. Analysis of pro- and antioxidant activity of blood in women with different phenotypes of polycystic ovary syndrome and infertility. Obstetrics and gynecology. 2017; 8: 86-91. (in Russian)]. https://dx.doi.org/10.18565/aig.2017.8.86-91.
Genazzani A.D. Inositol as putative integrative treatment for PCOS. Reprod. Biomed. Online. 2016; 33(6): 770-80. https://dx.doi.org/10.1016/j.rbmo.2016.08.024.
Pundir J., Psaroudakis D., Savnur P., Bhide P., Sabatini L., Teede H. et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018; 125(3): 299-308. https://dx.doi.org/10.1111/1471-0528.14754.
Iervolino M., Lepore E., Forte G., Laganà A.S., Buzzaccarini G., Unfer V. Natural molecules in the management of polycystic ovary syndrome (PCOS): An analytical review. Nutrients. 2021; 13(5): 1677. https://dx.doi.org/10.3390/nu13051677.
Facchinettia F., Appetecchia M., Aragona C., Bevilacqua A, Bezerra Espinola M.S., Bizzarri M. et al. Experts opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin. Drug Metab. Toxicol. 2020; 16(3):255-74. https://dx.doi.org/10.1080/17425255.2020.1737675.
Сапрыкина Л.В., Гульшин В.А. Возможности контроля овуляции у пациенток с синдромом поликистозных яичников на фоне терапии. РМЖ. 2018; 5(1): 29-32. [Saprykina L.V., Gulshin V.A. Possibilities of ovulation control in patients with polycystic ovary syndrome on the background of therapy. RMJ. 2018; 5(1): 29-32. (in Russian)].
ГОСТ Р ИСО 5479-2002. Проверка отклонения распределения вероятностей от нормального распределения: Национальный стандарт Российской Федерации. М.; 2002. 31с. (Статистические методы). [GOST R ISO 5479-2002. Checking the deviation of the probability distribution from the normal distribution: The National Standard of the Russian Federation. M., 2002. 31 p. (Statistical methods). (in Russian)].
Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur. Rev. Med. Pharmacol. Sci. 2019; 23(12): 5512-21. https://dx.doi.org/10.26355/eurrev_201906_18223.
Kalra B., Kalra S., Sharma J.B. The inositols and polycystic ovary syndrome. Indian J. Endocrinol. Metab. 2016; 20(5): 720-4. https://dx.doi.org/10.4103/2230- 8210.189231.
Обоскалова Т.А., Воронцова А.В., Звычайный М.А., Гущина Г.К., Майтесян М.М. Результаты применения комбинации миоинозитола и D-хироинозитола в соотношении 5:1 у женщин с синдромом поликистозных яичников. Гинекология. 2020; 22(6): 84-9. [Oboskalova T.A., Vorontsova A.V., Zvychainyi M.A., Gushchina K.G., Maitesian M.M. Results of treatment with myo-inositol and D-chiroinositol combination in ratio 5:1 in women with polycystic ovary syndrome. Gynecology. 2020; 22(6): 84-9. (in Russian)]. https://dx.doi.org/10.26442/20795696.2020.6.200548.
Januszewski M., Issat T., Jakimiuk A.A., Santor-Zaczynska M., Jakimiuk A.J. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol. Pol. 2019; 90(1): 7-10. https://dx.doi.org/10.5603/GP.2019.0002.
Mendoza N., Diaz-Ropero M.P., Aragon M., Maldonado V., Llaneza P., Lorente J. et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol. Endocrinol. 2019; 35(8): 695-700. https://dx.doi.org/10.1080/09513590.2019.1576620.
Mendoza N., Galan M.I., Molina C., Mendoza-Tesarik R., Conde C., Mazheika M. et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol. Endocrinol. 2020; 36(5): 398-401. https://dx.doi.org/10.1080/09513590.2019.1681959.
Malvasi A., Casciaro F., Minervini M., Kosmas I., Mynbaev O.A., Pacella E. et al. Myoinositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur. Rev. Med. Pharmacol. Sci. 2014; 18(2): 270-4.
Громова О.А., Андреева Е.Н., Торшин И.Ю., Тапильская Н.Г., Уварова Е.В. Системно-биологический анализ ролей марганца в акушерстве и гинекологии: репродуктивное здоровье женщины, регуляция менструального цикла и профилактика пороков развития плода. Вопросы гинекологии, акушерства и перинатологии. 2020; 19(1): 103-13. [Gromova O.A., Andreeva E.N., Torshin I.Yu., Tapil'skaya N.I., Uvarova E.V. A systemic biological analysis of the role ofmanganese in obstetrics and gynaecology: women’s reproductive health, menstrual cycle regulation and prevention of fetal malformations. Issues of Gynecology, Obstetrics and Perinatology. 2020; 19(1): 103-13. (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2020-1-103-113.
Chang H., Xie L., Ge H., Qi W., Yan W., Duojia Z. et al. Effects of hyperhomocysteinaemia and metabolic syndrome on reproduction in women with polycystic ovary syndrome: a secondary analysis. Reprod. Biomed. Online. 2019; 38(6): 990-8. https://dx.doi.org/10.1016/j.rbmo. 2018.12.046.

Received 07.06.2022

Accepted 14.06.2022

Nyurzhanna H. Khadzhieva, PhD, obstetrician-gynecologist, Central Clinical Hospital "RZD-Medicine", +7(499)262-88-89, nurzhanna@yandex.ru,
https://orcid.org/0000-0002-5520-281Х, 107078, Russia, Moscow, Novaya Basmannaya str., 5.

Conflicts of interest: The author declares that there are no conflicts of interest.
Funding: The investigation has not been sponsored.
Patient Consent for Publication: All patients provided informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Khadzhieva N.Kh. Alternative solution
for menstrual cycle normalization in polycystic ovary syndrome.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2022; 6: 122-128 (in Russian)
https://dx.doi.org/10.18565/aig.2022.6.122-128

Alternative solution for menstrual cycle normalization in polycystic ovary syndrome

Khadzhieva N.Kh.

Keywords

References

About the Authors

Similar Articles